日本癌症免疫疗法市场报告（按疗法类型、应用、最终用户和地区划分，2026-2034年）

2025年，日本癌症免疫疗法市场规模达80.842亿美元。展望未来， IMARC Group预计到2034年，该市场规模将达到150.233亿美元，2026年至2034年期间的复合年增长率（CAGR）为7.13%。推动市场成长的因素有很多，包括癌症发生率的上升、政府的支持性项目以及医疗保险的普及。

本报告解答的关键问题：

• 日本癌症免疫疗法市场目前表现如何？未来几年又将如何发展？
• 新冠疫情对日本癌症免疫疗法市场产生了哪些影响？
• 日本癌症免疫疗法市场按疗法类型分類的组成是怎样的？
• 日本癌症免疫疗法市场按应用领域分類的组成是怎样的？
• 日本癌症免疫疗法市场以最终用户分類的组成是怎样的？
• 日本癌症免疫疗法市场价值链的各个阶段有哪些？
• 日本癌症免疫疗法的关键驱动因素和挑战是什么？
• 日本癌症免疫疗法市场的结构是怎么样的？主要参与者有哪些？
• 日本癌症免疫疗法市场的竞争程度如何？

目录

第一章：序言

第二章：范围与方法

• 研究目标
• 利害关係人
• 数据来源
• 市场估算
• 预测方法

第三章：执行概要

第四章：日本癌症免疫疗法市场－简介

• 概述
• 市场动态
• 产业趋势
• 竞争情报

第五章：日本癌症免疫疗法市场概况

• 历史及当前市场趋势（2020-2025）
• 市场预测（2026-2034）

第六章：日本癌症免疫疗法市场－依疗法类型划分

• 单株抗体
• 癌症疫苗
• 检查点抑制剂
• 免疫调节剂
• 其他的

第七章：日本癌症免疫疗法市场－按应用领域细分

• 肺癌
• 乳癌
• 大肠直肠癌
• 黑色素瘤
• 摄护腺癌
• 头颈癌
• 其他的

第八章：日本癌症免疫疗法市场－以最终用户划分

• 医院
• 癌症研究中心
• 诊所
• 其他的

第九章：日本癌症免疫疗法市场－按地区划分

• 关东地区
• 关西/近畿地区
• 中部/中部地区
• 九州·冲绳地区
• 东北部地区
• 中国地区
• 北海道地区
• 四国地区

第十章：日本癌症免疫疗法市场－竞争格局

• 概述
• 市场结构
• 市场参与者定位
• 最佳制胜策略
• 竞争格局分析
• 公司评估象限

第十一章：关键参与者简介

第十二章：日本癌症免疫疗法市场—产业分析

• 驱动因素、限制因素和机会
• 波特五力分析
• 价值链分析

第十三章：附录

Japan cancer immunotherapy market size reached USD 8,084.2 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 15,023.3 Million by 2034, exhibiting a growth rate (CAGR) of 7.13% during 2026-2034. The market is being propelled by several significant factors, including an increasing incidence of cancer cases, supportive government programs, and the widespread accessibility of medical insurance.

Cancer is a medical condition characterized by the uncontrolled growth and spread of certain cells in the body to various parts. Its development is often linked to factors such as alcohol or tobacco consumption, an unhealthy diet, exposure to air pollution, and a lack of physical activity. Individuals affected by cancer can experience significant health challenges, including feelings of anxiety, depression, fear of mortality, pain, stress, and even thoughts of suicide. Immunotherapy is an approach to cancer treatment involving the use of antibodies that bind to and inhibit the activity of proteins produced by cancer cells. This method helps strengthen the immune system's ability to identify and eliminate abnormal cancer cells within the body. Consequently, it finds widespread application in the treatment of various cancer types, including lung, breast, colorectal, melanoma, prostate, head and neck, thyroid, kidney, liver, cervical, bladder, ovarian, and skin cancers.

Japan Cancer Immunotherapy Market Trends:

In the context of the Japanese market, several significant factors are positively impacting the cancer immunotherapy sector. One of the primary drivers is the rising number of cancer cases, attributed to poor dietary habits and exposure to harmful substances among individuals worldwide. Additionally, there is a growing awareness regarding diverse cancer treatment options among the global population, contributing to market expansion. Furthermore, the increasing adoption of cancer immunotherapies is driven by their ability to offer prolonged progression-free survival (PFS) and overall survival (OS) compared to traditional anti-tumor therapies. The availability and accessibility of medical insurance, alongside rising healthcare expenditure, are presenting attractive growth prospects for industry investors. Moreover, there is a growing demand for treatment approaches with fewer adverse effects, which aligns with the increasing approval of novel immunotherapies and fuels market growth. Government agencies and non-profit organizations in various countries are actively promoting the adoption of cancer immunotherapy through widespread awareness campaigns focused on cancer prevention. Lastly, the market benefits from ongoing technological advancements in cancer treatment therapies, which are enhancing the efficiency of disease management strategies. These factors collectively contribute to the positive growth trajectory of the cancer immunotherapy market in Japan.

Japan Cancer Immunotherapy Market Segmentation:

Therapy Type Insights:

• Monoclonal Antibodies
• Cancer Vaccines
• Checkpoint Inhibitors
• Immunomodulators
• Others

Application Insights:

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Melanoma
• Prostate Cancer
• Head and Neck Cancer
• Others

End User Insights:

• Hospitals
• Cancer Research Centers
• Clinics
• Others

Regional Insights:

• Kanto Region
• Kansai/Kinki Region
• Central/ Chubu Region
• Kyushu-Okinawa Region
• Tohoku Region
• Chugoku Region
• Hokkaido Region
• Shikoku Region
• The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

• How has the Japan cancer immunotherapy market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan cancer immunotherapy market?
• What is the breakup of the Japan cancer immunotherapy market on the basis of therapy type?
• What is the breakup of the Japan cancer immunotherapy market on the basis of application?
• What is the breakup of the Japan cancer immunotherapy market on the basis of end user?
• What are the various stages in the value chain of the Japan cancer immunotherapy market?
• What are the key driving factors and challenges in the Japan cancer immunotherapy?
• What is the structure of the Japan cancer immunotherapy market and who are the key players?
• What is the degree of competition in the Japan cancer immunotherapy market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Cancer Immunotherapy Market - Introduction

• 4.1 Overview
• 4.2 Market Dynamics
• 4.3 Industry Trends
• 4.4 Competitive Intelligence

5 Japan Cancer Immunotherapy Market Landscape

• 5.1 Historical and Current Market Trends (2020-2025)
• 5.2 Market Forecast (2026-2034)

6 Japan Cancer Immunotherapy Market - Breakup by Therapy Type

• 6.1 Monoclonal Antibodies
  • 6.1.1 Overview
  • 6.1.2 Historical and Current Market Trends (2020-2025)
  • 6.1.3 Market Forecast (2026-2034)
• 6.2 Cancer Vaccines
  • 6.2.1 Overview
  • 6.2.2 Historical and Current Market Trends (2020-2025)
  • 6.2.3 Market Forecast (2026-2034)
• 6.3 Checkpoint Inhibitors
  • 6.3.1 Overview
  • 6.3.2 Historical and Current Market Trends (2020-2025)
  • 6.3.3 Market Forecast (2026-2034)
• 6.4 Immunomodulators
  • 6.4.1 Overview
  • 6.4.2 Historical and Current Market Trends (2020-2025)
  • 6.4.3 Market Forecast (2026-2034)
• 6.5 Others
  • 6.5.1 Historical and Current Market Trends (2020-2025)
  • 6.5.2 Market Forecast (2026-2034)

7 Japan Cancer Immunotherapy Market - Breakup by Application

• 7.1 Lung Cancer
  • 7.1.1 Overview
  • 7.1.2 Historical and Current Market Trends (2020-2025)
  • 7.1.3 Market Forecast (2026-2034)
• 7.2 Breast Cancer
  • 7.2.1 Overview
  • 7.2.2 Historical and Current Market Trends (2020-2025)
  • 7.2.3 Market Forecast (2026-2034)
• 7.3 Colorectal Cancer
  • 7.3.1 Overview
  • 7.3.2 Historical and Current Market Trends (2020-2025)
  • 7.3.3 Market Forecast (2026-2034)
• 7.4 Melanoma
  • 7.4.1 Overview
  • 7.4.2 Historical and Current Market Trends (2020-2025)
  • 7.4.3 Market Forecast (2026-2034)
• 7.5 Prostate Cancer
  • 7.5.1 Overview
  • 7.5.2 Historical and Current Market Trends (2020-2025)
  • 7.5.3 Market Forecast (2026-2034)
• 7.6 Head and Neck Cancer
  • 7.6.1 Overview
  • 7.6.2 Historical and Current Market Trends (2020-2025)
  • 7.6.3 Market Forecast (2026-2034)
• 7.7 Others
  • 7.7.1 Historical and Current Market Trends (2020-2025)
  • 7.7.2 Market Forecast (2026-2034)

8 Japan Cancer Immunotherapy Market - Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Overview
  • 8.1.2 Historical and Current Market Trends (2020-2025)
  • 8.1.3 Market Forecast (2026-2034)
• 8.2 Cancer Research Centers
  • 8.2.1 Overview
  • 8.2.2 Historical and Current Market Trends (2020-2025)
  • 8.2.3 Market Forecast (2026-2034)
• 8.3 Clinics
  • 8.3.1 Overview
  • 8.3.2 Historical and Current Market Trends (2020-2025)
  • 8.3.3 Market Forecast (2026-2034)
• 8.4 Others
  • 8.4.1 Historical and Current Market Trends (2020-2025)
  • 8.4.2 Market Forecast (2026-2034)

9 Japan Cancer Immunotherapy Market - Breakup by Region

• 9.1 Kanto Region
  • 9.1.1 Overview
  • 9.1.2 Historical and Current Market Trends (2020-2025)
  • 9.1.3 Market Breakup by Therapy Type
  • 9.1.4 Market Breakup by Application
  • 9.1.5 Market Breakup by End User
  • 9.1.6 Key Players
  • 9.1.7 Market Forecast (2026-2034)
• 9.2 Kansai/Kinki Region
  • 9.2.1 Overview
  • 9.2.2 Historical and Current Market Trends (2020-2025)
  • 9.2.3 Market Breakup by Therapy Type
  • 9.2.4 Market Breakup by Application
  • 9.2.5 Market Breakup by End User
  • 9.2.6 Key Players
  • 9.2.7 Market Forecast (2026-2034)
• 9.3 Central/ Chubu Region
  • 9.3.1 Overview
  • 9.3.2 Historical and Current Market Trends (2020-2025)
  • 9.3.3 Market Breakup by Therapy Type
  • 9.3.4 Market Breakup by Application
  • 9.3.5 Market Breakup by End User
  • 9.3.6 Key Players
  • 9.3.7 Market Forecast (2026-2034)
• 9.4 Kyushu-Okinawa Region
  • 9.4.1 Overview
  • 9.4.2 Historical and Current Market Trends (2020-2025)
  • 9.4.3 Market Breakup by Therapy Type
  • 9.4.4 Market Breakup by Application
  • 9.4.5 Market Breakup by End User
  • 9.4.6 Key Players
  • 9.4.7 Market Forecast (2026-2034)
• 9.5 Tohoku Region
  • 9.5.1 Overview
  • 9.5.2 Historical and Current Market Trends (2020-2025)
  • 9.5.3 Market Breakup by Therapy Type
  • 9.5.4 Market Breakup by Application
  • 9.5.5 Market Breakup by End User
  • 9.5.6 Key Players
  • 9.5.7 Market Forecast (2026-2034)
• 9.6 Chugoku Region
  • 9.6.1 Overview
  • 9.6.2 Historical and Current Market Trends (2020-2025)
  • 9.6.3 Market Breakup by Therapy Type
  • 9.6.4 Market Breakup by Application
  • 9.6.5 Market Breakup by End User
  • 9.6.6 Key Players
  • 9.6.7 Market Forecast (2026-2034)
• 9.7 Hokkaido Region
  • 9.7.1 Overview
  • 9.7.2 Historical and Current Market Trends (2020-2025)
  • 9.7.3 Market Breakup by Therapy Type
  • 9.7.4 Market Breakup by Application
  • 9.7.5 Market Breakup by End User
  • 9.7.6 Key Players
  • 9.7.7 Market Forecast (2026-2034)
• 9.8 Shikoku Region
  • 9.8.1 Overview
  • 9.8.2 Historical and Current Market Trends (2020-2025)
  • 9.8.3 Market Breakup by Therapy Type
  • 9.8.4 Market Breakup by Application
  • 9.8.5 Market Breakup by End User
  • 9.8.6 Key Players
  • 9.8.7 Market Forecast (2026-2034)

10 Japan Cancer Immunotherapy Market - Competitive Landscape

• 10.1 Overview
• 10.2 Market Structure
• 10.3 Market Player Positioning
• 10.4 Top Winning Strategies
• 10.5 Competitive Dashboard
• 10.6 Company Evaluation Quadrant

11 Profiles of Key Players

• 11.1 Company A
  • 11.1.1 Business Overview
  • 11.1.2 Services Offered
  • 11.1.3 Business Strategies
  • 11.1.4 SWOT Analysis
  • 11.1.5 Major News and Events
• 11.2 Company B
  • 11.2.1 Business Overview
  • 11.2.2 Services Offered
  • 11.2.3 Business Strategies
  • 11.2.4 SWOT Analysis
  • 11.2.5 Major News and Events
• 11.3 Company C
  • 11.3.1 Business Overview
  • 11.3.2 Services Offered
  • 11.3.3 Business Strategies
  • 11.3.4 SWOT Analysis
  • 11.3.5 Major News and Events
• 11.4 Company D
  • 11.4.1 Business Overview
  • 11.4.2 Services Offered
  • 11.4.3 Business Strategies
  • 11.4.4 SWOT Analysis
  • 11.4.5 Major News and Events
• 11.5 Company E
  • 11.5.1 Business Overview
  • 11.5.2 Services Offered
  • 11.5.3 Business Strategies
  • 11.5.4 SWOT Analysis
  • 11.5.5 Major News and Events

12 Japan Cancer Immunotherapy Market - Industry Analysis

• 12.1 Drivers, Restraints, and Opportunities
  • 12.1.1 Overview
  • 12.1.2 Drivers
  • 12.1.3 Restraints
  • 12.1.4 Opportunities
• 12.2 Porters Five Forces Analysis
  • 12.2.1 Overview
  • 12.2.2 Bargaining Power of Buyers
  • 12.2.3 Bargaining Power of Suppliers
  • 12.2.4 Degree of Competition
  • 12.2.5 Threat of New Entrants
  • 12.2.6 Threat of Substitutes
• 12.3 Value Chain Analysis

13 Appendix